Developer docs
API playgroundTry for free, no card

Search company profiles

Lucid Psycheceuticals

Full company profile

uuid00083cp

Namestring
Lucid Psycheceuticals
Legal namestring
Lucid Psycheceuticals Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Lucid Psycheceuticals Inc. is a Toronto-based, pre-revenue specialty biopharmaceutical company founded in 2020 that develops small molecule drugs inspired by the mechanisms of action of psychedelics. The company targets three therapeutic areas — mental health disorders (including major depressive disorder), neurodegenerative disorders (Alzheimer's, Parkinson's, multiple sclerosis and related prodromal conditions), and inflammatory/immunology disorders — with a stated mission of pursuing 'total brain health.' Its lead candidate, Lucid-201, is a known molecule with clinical proof of efficacy in MDD that has been short-listed for further development by the Lucid team. The company's pipeline includes additional new chemical entities (NCEs) acquired through an exclusive worldwide license from University Health Network (UHN) in Toronto in May 2021, along with associated patents and preclinical efficacy data. The scientific approach emphasizes novel small molecule therapeutics aimed at preventing or potentially reversing neurodegeneration, distinguishing it from first-generation psychedelic-assisted therapy models.

The company is a wholly-owned subsidiary of FSD Pharma Inc. (NASDAQ: HUGE, CSE: HUGE, FRA: 0K9), a publicly-traded biopharmaceutical company, which provides corporate structure and financial backing. Lucid operates with 1-10 employees, is headquartered at 243 College Street, Suite 101, Toronto, and is led by founder and CEO Lakshmi Kotra. It pursues standard FDA and Health Canada regulatory pathways for its drug candidates and is actively recruiting across scientific, regulatory, IP, and business development functions.

Lucid's business model is a traditional pre-commercial pharmaceutical development model: the company is pre-revenue, generates no product sales, and expects any future revenue to come from commercialization of approved drugs through pharmaceutical sales channels or potential out-licensing deals. There are no current customers, no commercial pricing, and no active distribution channels. Customer segments are defined by future end-use cases — patients with MDD, neurodegenerative disease, and inflammatory disorders — rather than paying B2B clients. Marketing today is limited to a corporate website, LinkedIn, and Twitter presence aimed at investors, partners, and prospective talent.

Short descriptiontext

Lucid Psycheceuticals is a Toronto-based, pre-revenue biopharmaceutical company developing psychedelics-inspired small molecule drugs for mental health, neurodegenerative, and inflammatory disorders, and operates as a wholly-owned subsidiary of FSD Pharma Inc.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic pharmaceutical development, small molecule therapeutics, neurodegenerative disorder treatments, mental health drug discovery, inflammatory disorder drugs
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Sales
TypeOne Time License
Description

Pre-revenue biotech company. Future revenue expected from commercialization of novel therapeutic drugs following successful clinical development and regulatory approval. Revenue model will likely involve direct pharmaceutical product sales.

lucidpsycheceuticals.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lucid Psycheceuticals is a pre-revenue specialty psychedelic pharmaceutical company developing small molecule drugs inspired by the mechanisms of action of psychedelics. The company is advancing three drug pipelines targeting mental health disorders (led by Lucid-201 for major depressive disorder), neurodegenerative disorders (such as Alzheimer's, Parkinson's, and multiple sclerosis), and inflammatory disorders, with its core intellectual property consisting of an exclusive worldwide license to new chemical entities (NCEs) from University Health Network in Toronto, Canada.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Clinical proof of efficacy demonstrated for Lucid-201 in major depressive disorder (MDD)
Product overview1 text field

Lucid Psycheceuticals is a psychedelics-inspired biotech company developing novel small molecule drugs for neuro and inflammatory disorders. The company has a pipeline of molecules targeting mental health disorders (including Lucid-201 for major depressive disorder), neurodegenerative disorders, and inflammatory disorders. In May 2021, Lucid acquired an exclusive worldwide license to new chemical entities (NCEs), associated patents, and preclinical efficacy data from University Health Network (UHN) in Toronto, Canada. The company operates as a wholly-owned subsidiary of FSD Pharma Inc.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-01
Description

Lucid completed the acquisition of exclusive worldwide license to new chemical entities (NCEs), associated patents and preclinical efficacy data from University Health Network (UHN) in Toronto, Canada. This partnership provides the company with its core IP portfolio and foundational technology for drug development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public clinical-stage mental health company developing psilocybin-based therapies for treatment-resistant depression. Directly comparable to Lucid as a psychedelic-inspired CNS therapeutics developer targeting MDD-related indications.

2MindMed
TypeDirect peer
Description

Public psychedelic-inspired biotech developing novel therapeutics for mental health and addiction. Closely comparable to Lucid's psychedelic-inspired small-molecule approach in CNS indications.

3Atai Life Sciences
TypeDirect peer
Description

Public clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health. Comparable platform approach and indication overlap with Lucid.

TypeDirect peer
Description

Public psychedelic therapeutics company developing deuterated psilocybin analogs and other psychedelic-inspired molecules for depression and CNS disorders. Comparable psychedelic-mechanism drug development focus.

TypeDirect peer
Description

Public clinical-stage company developing mebufotenin and other psychedelic-inspired therapies for treatment-resistant depression. Comparable psychedelic-mechanism approach and CNS indication focus.

TypeBroad incumbent
Description

Public CNS-focused biopharma with FDA-approved MDD therapy (Zurzuvae). Comparable focus on CNS therapeutics and MDD as a target indication, though operating at larger scale with broader portfolio.

TypeBroad incumbent
Description

Public CNS therapeutics company with FDA-approved MDD therapy (Auvelity). Comparable target indication (MDD) and small-molecule CNS approach at a more advanced commercial stage.

TypeBroad incumbent
Description

Large pharmaceutical company that brought Spravato (esketamine) to market for treatment-resistant depression. Comparable CNS/MDD therapeutic space and incumbent benchmark for psychedelic-adjacent regulatory approvals.

TypeEmerging player
Description

Small public CNS-focused biotech with pipeline assets in neurodegenerative and psychiatric indications. Comparable therapeutic area overlap (neurodegeneration, mental health) at similar early-stage scale.

TypeEmerging player
Description

Public clinical-stage biopharma using AI-driven drug repositioning/discovery in neuroscience and immuno-oncology. Comparably sized CNS-focused emerging player with small-molecule pipeline assets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lucid Psycheceuticals

Specialty Pharmaceuticalslucidpsycheceuticals.com

Lucid Psycheceuticals is a Toronto-based, pre-revenue biopharmaceutical company developing psychedelics-inspired small molecule drugs for mental health, neurodegenerative, and inflammatory disorders, and operates as a wholly-owned subsidiary of FSD Pharma Inc.

What Lucid Psycheceuticals does

Lucid Psycheceuticals Inc. is a Toronto-based, pre-revenue specialty biopharmaceutical company founded in 2020 that develops small molecule drugs inspired by the mechanisms of action of psychedelics. The company targets three therapeutic areas — mental health disorders (including major depressive disorder), neurodegenerative disorders (Alzheimer's, Parkinson's, multiple sclerosis and related prodromal conditions), and inflammatory/immunology disorders — with a stated mission of pursuing 'total brain health.' Its lead candidate, Lucid-201, is a known molecule with clinical proof of efficacy in MDD that has been short-listed for further development by the Lucid team. The company's pipeline includes additional new chemical entities (NCEs) acquired through an exclusive worldwide license from University Health Network (UHN) in Toronto in May 2021, along with associated patents and preclinical efficacy data. The scientific approach emphasizes novel small molecule therapeutics aimed at preventing or potentially reversing neurodegeneration, distinguishing it from first-generation psychedelic-assisted therapy models.

The company is a wholly-owned subsidiary of FSD Pharma Inc. (NASDAQ: HUGE, CSE: HUGE, FRA: 0K9), a publicly-traded biopharmaceutical company, which provides corporate structure and financial backing. Lucid operates with 1-10 employees, is headquartered at 243 College Street, Suite 101, Toronto, and is led by founder and CEO Lakshmi Kotra. It pursues standard FDA and Health Canada regulatory pathways for its drug candidates and is actively recruiting across scientific, regulatory, IP, and business development functions.

Lucid's business model is a traditional pre-commercial pharmaceutical development model: the company is pre-revenue, generates no product sales, and expects any future revenue to come from commercialization of approved drugs through pharmaceutical sales channels or potential out-licensing deals. There are no current customers, no commercial pricing, and no active distribution channels. Customer segments are defined by future end-use cases — patients with MDD, neurodegenerative disease, and inflammatory disorders — rather than paying B2B clients. Marketing today is limited to a corporate website, LinkedIn, and Twitter presence aimed at investors, partners, and prospective talent.

Lucid Psycheceuticals firmographics

Firmographics
Name
Lucid Psycheceuticals
Legal name
Lucid Psycheceuticals Inc.
Website
https://lucidpsycheceuticals.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Lucid Psycheceuticals is a Toronto-based, pre-revenue biopharmaceutical company developing psychedelics-inspired small molecule drugs for mental health, neurodegenerative, and inflammatory disorders, and operates as a wholly-owned subsidiary of FSD Pharma Inc.
Ownership category
akta.pro rank

Lucid Psycheceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Psychedelic pharmaceutical development
  • Small molecule therapeutics
  • Neurodegenerative disorder treatments
  • Mental health drug discovery
  • Inflammatory disorder drugs

Where Lucid Psycheceuticals is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Lucid Psycheceuticals business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Sales: Pre-revenue biotech company. Future revenue expected from commercialization of novel therapeutic drugs following successful clinical development and regulatory approval. Revenue model will likely involve direct pharmaceutical product sales.

Go-to-market motion1 record

Marketing channels3 records

Lucid Psycheceuticals product offering

Product offering

Core offering

Lucid Psycheceuticals is a pre-revenue specialty psychedelic pharmaceutical company developing small molecule drugs inspired by the mechanisms of action of psychedelics. The company is advancing three drug pipelines targeting mental health disorders (led by Lucid-201 for major depressive disorder), neurodegenerative disorders (such as Alzheimer's, Parkinson's, and multiple sclerosis), and inflammatory disorders, with its core intellectual property consisting of an exclusive worldwide license to new chemical entities (NCEs) from University Health Network in Toronto, Canada.

Product overview

Lucid Psycheceuticals is a psychedelics-inspired biotech company developing novel small molecule drugs for neuro and inflammatory disorders. The company has a pipeline of molecules targeting mental health disorders (including Lucid-201 for major depressive disorder), neurodegenerative disorders, and inflammatory disorders. In May 2021, Lucid acquired an exclusive worldwide license to new chemical entities (NCEs), associated patents, and preclinical efficacy data from University Health Network (UHN) in Toronto, Canada. The company operates as a wholly-owned subsidiary of FSD Pharma Inc.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Clinical proof of efficacy demonstrated for Lucid-201 in major depressive disorder (MDD)

Companies that use Lucid Psycheceuticals

Customer profile

Segments3 records

Ideal customer profiles3 records

Lucid Psycheceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Lucid Psycheceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • University Health Network (UHN)coreStrategic or Co-development Partner · 1 May 2021Lucid completed the acquisition of exclusive worldwide license to new chemical entities (NCEs), associated patents and preclinical efficacy data from University Health Network (UHN) in Toronto, Canada. This partnership provides the company with its core IP portfolio and foundational technology for drug development.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Lucid Psycheceuticals competitors and assessment

Company assessment

Direct peers

  • Compass Pathways: Public clinical-stage mental health company developing psilocybin-based therapies for treatment-resistant depression. Directly comparable to Lucid as a psychedelic-inspired CNS therapeutics developer targeting MDD-related indications.
  • MindMed: Public psychedelic-inspired biotech developing novel therapeutics for mental health and addiction. Closely comparable to Lucid's psychedelic-inspired small-molecule approach in CNS indications.
  • Atai Life Sciences: Public clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health. Comparable platform approach and indication overlap with Lucid.
  • Cybin: Public psychedelic therapeutics company developing deuterated psilocybin analogs and other psychedelic-inspired molecules for depression and CNS disorders. Comparable psychedelic-mechanism drug development focus.
  • GH Research: Public clinical-stage company developing mebufotenin and other psychedelic-inspired therapies for treatment-resistant depression. Comparable psychedelic-mechanism approach and CNS indication focus.

Broad incumbents

  • Sage Therapeutics: Public CNS-focused biopharma with FDA-approved MDD therapy (Zurzuvae). Comparable focus on CNS therapeutics and MDD as a target indication, though operating at larger scale with broader portfolio.
  • Axsome Therapeutics: Public CNS therapeutics company with FDA-approved MDD therapy (Auvelity). Comparable target indication (MDD) and small-molecule CNS approach at a more advanced commercial stage.
  • Janssen Pharmaceuticals (Johnson & Johnson): Large pharmaceutical company that brought Spravato (esketamine) to market for treatment-resistant depression. Comparable CNS/MDD therapeutic space and incumbent benchmark for psychedelic-adjacent regulatory approvals.

Emerging players

  • Seelos Therapeutics: Small public CNS-focused biotech with pipeline assets in neurodegenerative and psychiatric indications. Comparable therapeutic area overlap (neurodegeneration, mental health) at similar early-stage scale.
  • BioXcel Therapeutics: Public clinical-stage biopharma using AI-driven drug repositioning/discovery in neuroscience and immuno-oncology. Comparably sized CNS-focused emerging player with small-molecule pipeline assets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Lucid Psycheceuticals social profiles

Digital presence

Lucid Psycheceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lucid Psycheceuticals leadership team

Management profile

Number of profiles

Profiles1 record

Lucid Psycheceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lucid Psycheceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucid Psycheceuticals

What does Lucid Psycheceuticals do?

Lucid Psycheceuticals is a pre-revenue specialty psychedelic pharmaceutical company developing small molecule drugs inspired by the mechanisms of action of psychedelics. The company is advancing three drug pipelines targeting mental health disorders (led by Lucid-201 for major depressive disorder), neurodegenerative disorders (such as Alzheimer's, Parkinson's, and multiple sclerosis), and inflammatory disorders, with its core intellectual property consisting of an exclusive worldwide license to new chemical entities (NCEs) from University Health Network in Toronto, Canada.

Is Lucid Psycheceuticals a public or private company?

Lucid Psycheceuticals is a private company. It is classified as corporate owned and is currently operating.

When was Lucid Psycheceuticals founded?

Lucid Psycheceuticals was founded in 2020. It employs 1 to 10 people.

Where is Lucid Psycheceuticals based?

Lucid Psycheceuticals is headquartered in Toronto, Canada, in the North America region.

How does Lucid Psycheceuticals make money?

One revenue line is on record: pharmaceutical Drug Sales.

Who are Lucid Psycheceuticals's main competitors?

Direct peers on record are Compass Pathways, MindMed, Atai Life Sciences, Cybin and GH Research. Broad incumbents are Sage Therapeutics, Axsome Therapeutics and Janssen Pharmaceuticals (Johnson & Johnson). Emerging players are Seelos Therapeutics and BioXcel Therapeutics.

Does Lucid Psycheceuticals have an API?

No public API is recorded for Lucid Psycheceuticals.

What industry is Lucid Psycheceuticals in?

Lucid Psycheceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals